The article reports that 41% of patients in the GRAVITAS trial had high on-treatment platelet reactivity after receiving Plavix®. This is consistent with previous studies that show that up to 1 in 3 patients may not be responding adequately to their antiplatelet therapy. Numerous factors are associated with low platelet response, including pre-existing health conditions such as diabetes, interference from other medications, non compliance and genetics.
"GRAVITAS underscores the need to develop more individualized treatment strategies for cardiovascular patients," said Timothy I. Still, President and CEO of Accumetrics. "As more antiplatelet treatment options become available, the VerifyNow System continues to help clinicians better assess a patient's response to therapy."
The VerifyNow System is widely used in various clinical settings where antiplatelet medications are prescribed to reduce the occurrence of future thrombotic events such as heart attack and stroke.
(1) Price MJ, Berger PB, Teirstein PS, et al. Standard- vs High-Dose Clopidogrel Based on Platelet Function Testing After Percutaneous Coronary Intervention. JAMA.2011;3051097-1105.
AboutAccumeicsAccumetrics is committed to advancing medical understanding of platelet function and enhancing quality of care for patients receiving antiplatelet therapies by providing industry-leading and widely accessible diagnostic tests for rapid platelet function assessment.
Accumetrics' VerifyNow System is the first rapid and easy-to-use platform to help physicians determine an individual's response to multiple antiplatelet agents. Addressing every major antiplatelet drug, including FDA-cleared products for aspirin, P2Y12 inhibitors (e.g. prasugrel (Effient®) and clopidogrel (Plavix®)), and GP IIb/IIIa inhibitors (e.g. ReoPro® and Integrilin®), the VerifyNow Sy
|SOURCE Accumetrics, Inc.|
Copyright©2010 PR Newswire.
All rights reserved